Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib

Background Crizotinib is associated with a favorable survival benefit in patients with ALK‐positive non‐small cell lung cancer (NSCLC); however, a subset of patients harboring ALK rearrangement shows a poor response.